CSL Behring bags Hemgenix EC approval for treatment of Hemophilia B

German-based biotechnology company CSL Behring has received conditional marketing authorization (CMA) from the European Commission (EC) for its Hemgenix (etranacogene dezaparvovec) indicated for the treatment ... Read More